ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

Chen, Ming-kun; Liang, Zhi-jian; Luo, Dao-Sheng; Xue, Kang-yi; Liao, De-ying; Li, Zheshen; Yu, Yuzhong; Chen, Zhe-Sheng*; Zhao, Shan-Chao*南方医科大学
Frontiers in Pharmacology2022-2-17DOI: 10.3389/fphar.2022.843110
4被引14阅读
引用收藏
分享

摘要

Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy.Methods: Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival.Results: Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1-2.Conclusion: Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-nai''ve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment.

学科与关键词

关键词
metastatic castration-resistant prostate cancersequential therapycombined therapydocetaxelabirateroneorteronelenzalutamide
相关
加载中…
  • Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
    You, Xiangyun; Huang, Shan; Wang, Xin'an; Yi, Cheng; Gong, Niandong; Yu, Junfeng; Xu, Chengdang*; Xiang, Zhendong*Frontiers in Endocrinology, 2023, 13: 1125838.被引 1
  • Current therapy and drug resistance in metastatic castration-resistant prostate cancer
    Cai, Maoping; Song, Xian-Lu; Li, Xin-An; Chen, Mingkun; Guo, Jiading; Yang, Dong Hua*; Chen, Zhanghui*; Zhao, Shan-Chao*DRUG RESISTANCE UPDATES, 2023, 68: 100962.被引 19
  • Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
    R, NandhaJournal of Postgraduate Medicine, 2012, 58(3): 203.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-02-17
卷期
第 13 卷
页码
843110
DOI
10.3389/fphar.2022.843110
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81972394]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010066]; President Foundation of the Third Affiliated Hospital of Southern Medical University [YM2021010, YM2021011]

作者

  • C

    Chen, Ming-kun (第一作者)

    southern med univ

  • L

    Liang, Zhi-jian

    southern med univ

查看全部 9 位作者收起作者
  • L

    Luo, Dao-Sheng

    southern med univ

  • X

    Xue, Kang-yi

    southern med univ

  • L

    Liao, De-ying

    southern med univ

  • L

    Li, Zheshen

  • Y

    Yu, Yuzhong

    southern med univ

  • C

    Chen, Zhe-Sheng (通讯)

  • Z

    Zhao, Shan-Chao (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417